Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho

Clin Infect Dis. 2023 Nov 11;77(9):1318-1321. doi: 10.1093/cid/ciad390.

Abstract

In the Viral Load Cohort North-East Lesotho (VICONEL) human immunodeficiency virus cohort, 14 242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021. Rates of viral suppression to <50 copies/mL were 84.8%, 93.9%, and 95.4% before, 12 months after, and 24 months after transition, respectively. Sex, age, pretransition viral load, and treatment backbone correlated with 24-month viremia.

Keywords: Africa; integrase inhibitors; observational study; treatment failure; treatment outcome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents* / therapeutic use
  • HIV
  • HIV Infections* / drug therapy
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Lesotho / epidemiology
  • Treatment Outcome
  • Viral Load

Substances

  • dolutegravir
  • Anti-HIV Agents
  • Heterocyclic Compounds, 3-Ring